RecruitingNot applicableNCT07572773
Official study title

CHAMP Lung Cancer Screening Program

Study summary

The U.S. Preventive Services Task Force recommends annual lung cancer screening (LCS) with low-dose CT for adults aged 50-80 with a ≥20 pack-year smoking history who currently smoke or quit within the past 15 years. Despite insurance coverage, only 17% of eligible Iowans were screened in 2024. Barriers include the complexity of screening and competing demands in primary care. To address these challenges, investigators propose a two-part intervention: a blood-based screening test to simplify LCS and a community pharmacist-led referral program integrated into routine pharmacy care. Eligible patients will be identified at Greenwood Pharmacy in Waterloo, Iowa. Interested individuals will be consented by a pharmacist and engaged in shared decision-making about LCS. Participants may decline screening, complete the DELFI Diagnostics FirstLook lung cancer screening blood test, or pursue CT screening through their primary care physician. Those choosing the blood test will be referred to Cedar Valley Family Medicine. Patients with a positive result will complete a standard shared decision-making visit with their PCP and, if appropriate, undergo confirmatory CT imaging. Patients with a negative result will enter a screening cohort and be re-screened annually for an additional year.

Ask AI to explain this study
Start here

Key things to know

Main goalScreening

This describes the study’s primary purpose.

What is being studiedDELFI Diagnostics FirstLook Lung Cancer Screening Blood Test and Low-Does CT Scan

The study team can explain what participation involves.

Who it may be forLung Cancer · Early Lung Cancer Detection

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 16, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Interventional

Where is it offered?3 U.S. locations

Locations may change over time.

Who runs it?Jill Kolesar

Study sponsor

01
Study overview

What this study is about

Purpose
Screening
Study type
Interventional
Phase
Not applicable
Sponsor
Jill Kolesar
Interventions being studied
Diagnostic Test: DELFI Diagnostics FirstLook Lung Cancer Screening Blood Test; Diagnostic Test: Low-Does CT Scan
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • aged 50-77
  • smoking pack-year history of ≥ 20 years
  • current smoker or quit smoking 15 or less years ago
  • ability to understand and willingness to sign a written informed consent document
Reasons someone may not be able to joinExclusion criteria
  • self-report of lung cancer screening in the last 12 months
  • psychiatric illness/social situations that would limit compliance with study requirements

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of IowaIowa City, Iowa
  • Cedar Valley Primary Care & Walk-In ClinicWaterloo, Iowa
  • Greenwood Pharmacy and Compounding CenterWaterloo, Iowa

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 16, 2026. Always confirm current availability with the study team.

View original record ↗